ѻý

<ѻý class="page-title">Meeting Coverage

ASCO GU

<ѻý class="page-description">American Society of Clinical Oncology Genitourinary Cancer Symposium
ASCO GU: Switch to Degarelix Slows PSA

ORLANDO -- PSA progression slowed significantly in prostate cancer patients switched to degarelix (Firmagon) after 12 months of leuprolide therapy, data from an open-label extension study showed.

image
<ѻý class="section_title">Latest ASCO GU Meeting Coverage
ASCO GU: Rise in PSA Slowed by Pomegranate

ORLANDO -- Prostate cancer patients had a six-month gain in PSA doubling time when treated with pomegranate extract, according to data reported here.

February 18, 2011
ASCO GU: Long Learning Curve for Robotic Prostate Removal

ORLANDO -- Three experienced surgeons needed more than 1,600 cases to achieve acceptable outcomes with robotic-assisted laparoscopic prostatectomy, data from a retrospective chart review showed.

February 16, 2011
ASCO GU: BP Reveals Hit or Miss for Targeted Tx

SAN FRANCISCO -- Early response to preoperative targeted therapy for metastatic renal cell carcinoma may indicate efficacy, while treatment-induced hypertension may be another marker after surgery, according to studies reported here.

March 9, 2010
ASCO GU: Urine Screening Not Worth the Money in Bladder CA

SAN FRANCISCO -- Adding urine tests to standard cytoscopy for surveillance after non-muscle invasive bladder cancer may increase cost without boosting detection, according to a prospective cost-effectiveness study.

March 4, 2010